PWS DESK Independent handbook · 中文 ES

This site is not the association. US crisis calls: pwsausa.org · 941-312-0400. We do not answer that phone.

Comic drawing of hormone vials and a DEXA bone density ledger on a medical desk
PUBERTY AND BONE HEALTH

Hypogonadism and sex hormones in PWS: puberty, bone density, and behaviour

Adolescence brings a complex endocrine dilemma for families: puberty often starts on its own, but then stops progressing before sexual maturity. Without sex steroids, bone density plummets into osteopenia, while hypotonia weakens the spine. Yet many parents and clinicians delay testosterone or estrogen replacement out of fear of explosive aggression or unpredictable bleeding. Two large 2026 clinical cohorts provide long-needed answers on bone stabilization, behavioral outcomes, and surveillance protocols.

ANSWER CAPSULE

Most adolescents with Prader-Willi syndrome enter puberty spontaneously, but sexual development commonly arrests mid-course due to hypothalamic dysfunction. Over 75 percent develop hypogonadism requiring hormone replacement. A 2026 longitudinal cohort showed gradual testosterone therapy stabilized bone mineral density and improved lean body mass without triggering overall behavioral deterioration or severe aggressive outbursts.

PWS Hypogonadism Quantitative Outcomes (2026 Cohorts) Three-panel quantitative bar chart showing spontaneous onset vs final hypogonadism (77% female, 88% male), femoral neck BMD Z-score (-1.5 vs 0.0), and 5-year Dutch male testosterone behavioral outcomes (68.2% no dose change, 6.8% stopped). 1. HYPOTHALAMIC ARREST (N=65) Spontaneous onset (63% F / 68% M) Confirmed hypogonadism: Female 77% Confirmed hypogonadism: Male 88% 77% FEMALE / 88% MALE Arrests at Tanner II-III before transition Adrenarche intact; central GnRH stalled 2. SKELETAL DEFICIT (DEXA) Femoral neck BMD Z-score scale 0.0 Norm Median -1.5 (IQR -2.2 to -0.8) Oral OCP drop-out (bleeding): 44% Z-SCORE -1.5 AT TRANSFER GH alone cannot close epiphyses Transdermal E2 prevents 44% OCP dropout 3. 5-YR TRT COHORT (N=59) No behavioral dose change: 68.2% Temporary titration pause: 25.0% Stopped for behavior: 6.8% 68.2% ZERO DOSE CHANGE DBC-P total behavior score stable Lumbar BMD SDS & lean mass preserved
WHAT 2024 TO 2026 STUDIES REVEAL

Separating real endocrine outcomes from behavioral assumptions

For decades, sex steroid replacement in Prader-Willi syndrome sat in an uneasy clinical shadow. Because temper tantrums, skin-picking, and emotional inflexibility are well-known behavioral traits, parents and physicians worried that administering testosterone would fuel aggression or behavioral crises. At the same time, in females with PWS, starting standard oral contraceptive pills frequently caused unpredictable breakthrough bleeding, leading 44 percent of young women to abandon therapy entirely.

Two groundbreaking 2026 papers in Clinical Endocrinology have reshaped this landscape. An Australian 35-year retrospective cohort (n=65) documented that while puberty onset appeared normal in approximately two-thirds of patients (median age 10.3 years in girls and 12.3 years in boys), sexual development failed to progress to full maturity. True hypogonadism was diagnosed in 77 percent of females and 88 percent of males prior to adult transfer, with femoral neck bone mineral density z-scores sitting at a median of -1.5. In parallel, a Dutch 5-year longitudinal cohort of 59 males aged over 14 years demonstrated that low-dose, carefully titrated testosterone replacement stabilized lumbar spine and whole-body bone density SDS while significantly improving lean body mass. Standardized Developmental Behaviour Checklist (DBC-P) total scores showed no statistically significant worsening, with 68.2 percent requiring no modification in therapy.

Why spontaneous puberty stalls: adrenarche versus central gonadarche

A frequent trap in pediatric visits is mistaking pubic or axillary hair at age nine or ten for an intact reproductive axis. In Prader-Willi syndrome, premature adrenarche (maturation of the adrenal zona reticularis with rising DHEA-S) occurs in up to a third of children and is completely independent of the hypothalamic-pituitary-gonadal axis. Even when true central gonadarche begins, with breast budding in girls (Tanner stage B2) or early testicular enlargement above 4 mL in boys (Tanner stage G2), hypothalamic GnRH pulse generation typically loses amplitude as adolescence progresses.

Furthermore, endocrine profiling across 2024 to 2026 cohorts confirms that PWS hypogonadism is often mixed rather than purely central. Boys with cryptorchidism (present in over 80 percent of male infants with PWS, even after early orchidopexy) frequently exhibit primary Sertoli and Leydig cell exhaustion during mid-puberty, reflected by declining inhibin B and rising FSH alongside low-normal LH and morning testosterone. In girls, anti-Mullerian hormone (AMH) and estradiol often plateau at early pubertal levels, leaving the uterus under-estrogenized and preventing spontaneous menarche. If families and clinicians simply wait for puberty to finish on its own, the critical window of adolescent peak bone mass accrual between ages 12 and 18 slips away.

The 2026 male testosterone protocol and female transdermal estradiol titration

Why did the 2026 Dutch cohort of 59 males achieve such high behavioral tolerability when older anecdotal reports warned of temper flares? The decisive variable was starting dose and titration cadence. Rather than initiating adult-strength depot testosterone injections, Dutch endocrinologists started pubertal induction at low doses (either daily transdermal testosterone gel or low-dose intramuscular testosterone esters stepped up every 3 to 6 months over two to three years) while keeping patients on stable recombinant human growth hormone. Across five years of follow-up, DBC-P total scores and disruptive/antisocial subscales showed no cohort-level deterioration. When transient irritability occurred (in roughly a quarter of patients), holding the current dose step or switching from monthly depot peaks to daily transdermal gel resolved symptoms in the vast majority, leaving only 6.8 percent who discontinued permanently.

On the female side, a 2025 clinical series in the Journal of Pediatric and Adolescent Gynecology (n=68) pinpointed why 44 percent of young women with PWS stopped hormone therapy: starting full-dose combined oral contraceptive pills (OCPs) on an unprimed, hypoplastic endometrium caused erratic breakthrough bleeding, hygiene distress, and behavioral agitation around unexpected blood on clothing. Endocrine clinics that instead initiate ultra-low-dose transdermal 17-beta-estradiol patches (building endometrial thickness gradually over 12 to 24 months before adding cyclic micronized progesterone, or transitioning to a levonorgestrel intrauterine system or continuous suppression once maturity is reached) achieve far higher continuation rates and predictable bleeding control.

Bone mineral density, scoliosis hardware, and the 18+ adult transition

Parents often ask whether daily growth hormone injections are enough to protect their teenager's skeleton. Growth hormone stimulates linear cartilage growth and osteoblast turnover, but sex steroids (estradiol in both sexes, including estradiol aromatized from testosterone in males) are biologically required to close the epiphyseal growth plates, inhibit osteoclast-mediated trabecular resorption, and lock calcium into cortical bone. When hypogonadism goes untreated during the teen years, femoral neck bone mineral density drops to a median z-score of -1.5 (interquartile range -2.2 to -0.8), placing young adults directly on the threshold of clinical osteoporosis.

This skeletal deficit carries immediate consequences for orthopedic care. Over 40 to 60 percent of adolescents with PWS develop scoliosis or kyphoscoliosis. When spinal fusion surgery is required, low vertebral bone mineral density and weak paravertebral lean muscle mass increase the risk of pedicle-screw loosening, rod junction failure, and prolonged immobilization (see surgery & anaesthesia). Before transferring from pediatric to adult care at age 18, every family should secure a written endocrine transition packet containing: (1) a baseline and two-year interval DEXA scan of the lumbar spine and femoral neck, (2) morning LH, FSH, total testosterone or ultrasensitive estradiol, and SHBG levels, (3) 25-hydroxyvitamin D and dietary calcium targets, and (4) an explicit behavioral and menstrual log so the receiving adult endocrinologist never stops hormone replacement abruptly.

Clinical questionOlder assumption2024 to 2026 evidence
Spontaneous pubertal signsDevelopment of pubic hair or early breast budding guarantees normal gonadal axis function.Premature adrenarche is common, but central gonadarche arrests in 77 percent of females and 88 percent of males. Incomplete maturation requires formal endocrine evaluation. See growth hormone.
Testosterone and behavioral rageTestosterone replacement therapy inevitably causes severe aggressive outbursts and temper tantrums.A 2026 5-year longitudinal study of 59 males found no change in DBC-P total behavior scores. Over 68 percent had zero need for dose adjustments; only 6.8 percent permanently discontinued for behavior.
Bone mineral density and fracturesGrowth hormone alone is sufficient to protect bones throughout adulthood.Untreated hypogonadism causes rapid skeletal demineralization, with adolescent femoral neck z-scores averaging -1.5. Combining growth hormone with sex steroids maintains peak bone mass. See adulthood.
Hormone replacement in femalesStandard high-dose oral contraceptive pills should be started without specialized bleeding plans.A 2025 study showed a 44 percent discontinuation rate primarily due to unpredictable breakthrough bleeding. Gradual transdermal estradiol with cyclic micronized progesterone improves compliance.
Surgical considerationsSex hormone therapy has no impact on perioperative risk or recovery.Optimizing bone mineral density and paravertebral muscle mass reduces hardware complications in scoliosis spinal fusion. See surgery & anaesthesia.

Common questions

Does testosterone therapy worsen behavior or trigger rage in adolescents with PWS?

A 2026 longitudinal study of 59 males with PWS on growth hormone found that testosterone replacement therapy did not significantly change total behavior checklist scores over 5 years. Over 68 percent required no dose reductions or discontinuation due to behavior, and only 6.8 percent permanently stopped therapy. Starting at low doses and titrating slowly under endocrine supervision protects bone density while minimizing behavioral disruption.

Does spontaneous puberty mean a teenager with PWS does not have hypogonadism?

No. An Australian 35-year cohort published in 2026 found that while 63 percent of females and 68 percent of males enter puberty spontaneously, sexual maturation typically arrests mid-course. By transition age, 77 percent of females and 88 percent of males demonstrated true hypogonadism requiring hormone replacement. Early pubic hair often reflects premature adrenarche rather than intact gonadal function.

Why is hormone replacement therapy necessary if puberty is delayed?

Without sex hormones, adolescents with PWS face accelerated bone loss, with femoral neck bone mineral density z-scores averaging -1.5. Chronic hypogonadism also reduces lean muscle mass and worsens hypotonia. 2026 evidence demonstrates that pubertal hormone replacement stabilizes lumbar and whole-body bone density and improves lean body mass without increasing behavioral crises.

Sources: Clinical Endocrinology, 2026 · Clinical Endocrinology, 2026 · Journal of Pediatric and Adolescent Gynecology, 2025 · Frontiers in Endocrinology, 2024 · ClinicalTrials NCT00971555